Xinyan Zhu

Xinyan Zhu

Auto-generated profile, based on publicly available information

Xinyan Zhu

Hong Kong University of Science and Technology

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2025 in Journal of the American Chemical Society
Verified
Journal Article
Open access
SNShipeng Ning
Shipeng Ning
PSPing Shangguan
Ping Shangguan
XZXinyan Zhu
Xinyan Zhu
XOXinwen Ou
Xinwen Ou
KWKaiyuan Wang
Kaiyuan Wang
Ben Zhong TangBen Zhong Tang
Ben Zhong Tang
The immunosuppressive tumor microenvironment in triple-negative breast cancer could hinder the response to thorough immunotherapy and diminish the antitumor efficacy. Although the STING pathway emerges as a promising target to remedy defects, uncertain drug delivery might lead to off-target inflammatory reactions. Here, we manifest a novel phototheranostic agent with an aggregation-induced emission property that guided the pharmacological activation of a STING agonist for photothermal immunotherapy to create an immunologically "hot" tumor. A pyridinium rotor strategy is proposed to develop a positively charged TBTP-Bz, which is stably coincorporated with a STING agonist MSA-2 into thermal-responsive exosome-liposome hybrid nanoparticles for tumor-targeting delivery. TBTP-Bz exhibits aggregation-enhanced NIR-II emission and a photoacoustic signal, accomplishing real-time tumor tracking. Its photothermal stimulation induces immunogenic cancer cell death and promotes the precise release of MSA-2, thus boosting STING activation and STING-mediated type I interferon production. Significantly, single-dose photoimmunotherapy effectively suppresses abscopal tumor growth and provokes an immune memory effect to inhibit postsurgical recurrent and rechallenged tumors. This demonstrates promising clinical potential for poorly immunogenic breast cancer.

1 July 2024 in Bioactive Materials
Verified
Journal Article
Open access
HSHanchen Shen
Hanchen Shen
HWHongbin Wang
Hongbin Wang
JMJianlan Mo
Jianlan Mo
JZJianyu Zhang
Jianyu Zhang
CXChanghuo Xu
Changhuo Xu
Ben Zhong TangBen Zhong Tang
Ben Zhong Tang
Ultrahigh dose-rate (FLASH) radiotherapy is an emerging technology with excellent therapeutic effects and low biological toxicity. However, tumor recurrence largely impede the effectiveness of FLASH therapy. Overcoming tumor recurrence is crucial for practical FLASH applications. Here, we prepared an agarose-based thermosensitive hydrogel containing a mild photothermal agent (TPE-BBT) and a glutaminase inhibitor (CB-839). Within nanoparticles, TPE-BBT exhibits aggregation-induced emission peaked at 900 nm, while the unrestricted molecular motions endow TPE-BBT with a mild photothermy generation ability. The balanced photothermal effect and photoluminescence are ideal for phototheranostics. Upon 660-nm laser irradiation, the temperature-rising effect softens and hydrolyzes the hydrogel to release TPE-BBT and CB-839 into the tumor site for concurrent mild photothermal therapy and chemotherapy, jointly inhibiting homologous recombination repair of DNA. The enhanced FLASH radiotherapy efficiently kills the tumor tissue without recurrence and obvious systematic toxicity. This work deciphers the unrestricted molecular motions in bright organic fluorophores as a source of photothermy, and provides novel recurrence-resistant radiotherapy without adverse side effects.

19 May 2026 in ACS Nano
Verified
Journal Article
Closed access
XWXinyuan Wang
Xinyuan Wang
ZCZhongxin Chen
Zhongxin Chen
ZHZhubin Hu
Zhubin Hu
YZYu Zhang
Yu Zhang
XZXun Zhang
Xun Zhang
Ben Zhong TangBen Zhong Tang
Ben Zhong Tang

3 October 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
HSHanchen Shen
Hanchen Shen
XZXinyan Zhu
Xinyan Zhu
JZJianyu Zhang
Jianyu Zhang
CXChanghuo Xu
Changhuo Xu
JLJacky W. Y. Lam
Jacky W. Y. Lam
Ben Zhong TangBen Zhong Tang
Ben Zhong Tang
Organic dyes with photoluminescence in the second near-infrared window (NIR-II, 1000–1700 nm) are essential in bioimaging and optoelectronic devices. Photoluminescence quantum yield (PLQY) is their important performance indicator. Integrating sphere technology is effective in determining the absolute PLQY. However, the low emission brightness of most NIR-II organic fluorophores results in unacceptable errors. Therefore, the most common method for determining the PLQY is a relative approach using photoluminescence spectrometers and a standard reference like IR-26. Although the relative method can obtain accurate PLQY ratios between the samples and references, the specific PLQY value of IR-26 is not clearly defined, which is reported to range from 0.05% to 0.50%. Such a deviation can cause significant errors in relative PLQY measurements. In this study, a bright organic fluorophore called TPE-BBT exhibits a high PLQY of 4.17% in THF, which can be accurately measured using a commercially available integrating sphere. Using TPE-BBT as a standard reference, we have determined the PLQY values of IR-26 in DCE to be 0.0301% and IR-1061 in DCM to be 0.193%.

5 October 2026 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
XZXinyan Zhu
Xinyan Zhu
JLJunjun Li
Junjun Li
WYWenshan Yan
Wenshan Yan
LDLidong Du
Lidong Du
HSHanchen Shen
Hanchen Shen
Ben Zhong TangBen Zhong Tang
Ben Zhong Tang